Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

Detalles Bibliográficos
Autores principales: van der Schoot, Lara S., Atalay, Selma, Otero, Marisol E., Kievit, Wietske, van den Reek, Juul M.P.A., de Jong, Elke M.G.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087531/
https://www.ncbi.nlm.nih.gov/pubmed/35895852
http://dx.doi.org/10.1111/bjd.21797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087531/
https://www.ncbi.nlm.nih.gov/pubmed/35895852
http://dx.doi.org/10.1111/bjd.21797

Ejemplares similares